within Pharmacolibrary.Drugs.ATC.N;

model N03AB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fosphenytoin is a water-soluble prodrug of phenytoin, an antiepileptic medication used for the control of generalized tonic-clonic status epilepticus and prevention and treatment of seizures during neurosurgery. It is approved for intravenous or intramuscular use in situations where oral phenytoin is not feasible.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in healthy adult subjects, after intravenous administration; rapid conversion to phenytoin occurs in vivo. Parameters reflect fosphenytoin itself, not the phenytoin metabolite.</p><h4>References</h4><ol><li><p>Li, X, et al., &amp; Ding, Y (2023). Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers. <i>Frontiers in pharmacology</i> 14 1204075–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1204075&quot;>10.3389/fphar.2023.1204075</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38044946/&quot;>https://pubmed.ncbi.nlm.nih.gov/38044946</a></p></li><li><p>Browne, TR (1997). Fosphenytoin (Cerebyx). <i>Clinical neuropharmacology</i> 20(1) 1–12. DOI:<a href=&quot;https://doi.org/10.1097/00002826-199702000-00001&quot;>10.1097/00002826-199702000-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9037568/&quot;>https://pubmed.ncbi.nlm.nih.gov/9037568</a></p></li><li><p>Boucher, BA, et al., &amp; Kugler, AR (1996). The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. <i>Pharmacotherapy</i> 16(4) 638–645. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8840370/&quot;>https://pubmed.ncbi.nlm.nih.gov/8840370</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AB05;
